https://www.zacks.com/stock/news/2262530/exel-vs-regn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2262530
Apr 25, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
zc:6760043747133680424
0
https://www.zacks.com/commentary/2261192/top-stock-reports-for-danaher-regeneron-pharmaceuticals-palo-alto-networks?cid=CS-ZC-FT-research_daily-2261192
Apr 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
zc:817260156667333572
0
https://www.zacks.com/stock/news/2257993/biotech-stock-roundup-regn-sage-nmra-down-on-updates-itci-gains-on-study-success?cid=CS-ZC-FT-analyst_blog|stock_roundup-2257993
Apr 18, 2024 - Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
zc:8959759652210020379
0
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
zc:-5865686420277375127
0
https://www.zacks.com/stock/news/2256270/why-regeneron-regn-could-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2256270
Apr 16, 2024 - Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zc:3742466285535070840
0
https://www.zacks.com/stock/news/2252785/exel-or-regn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2252785
Apr 09, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
zc:-6254228627173850506
0
https://www.fool.com/investing/2024/03/28/stock-split-watch-are-these-2-top-growth-stocks/?source=iedfolrf0000001
Mar 28, 2024 - Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
0
fool:326808553711399268
0
https://www.zacks.com/commentary/2243512/top-research-reports-for-jpmorgan-chase-merck-sap?cid=CS-ZC-FT-research_daily-2243512
Mar 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP).
zc:8659119032620171639
0
https://www.zacks.com/stock/news/2243015/intellia-ntla-begins-dosing-in-phase-iii-attr-amyloidosis-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243015
Mar 19, 2024 - Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
zc:-3316277904804375071
0
https://www.zacks.com/stock/news/2240974/biotech-stock-roundup-amlx-acad-down-on-study-data-mrna-rgls-gain-on-updates-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2240974
Mar 14, 2024 - Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
zc:7324680728588329649
0